JP2017535533A - 高純度のアジルサルタンを調製するための方法 - Google Patents
高純度のアジルサルタンを調製するための方法 Download PDFInfo
- Publication number
- JP2017535533A JP2017535533A JP2017520351A JP2017520351A JP2017535533A JP 2017535533 A JP2017535533 A JP 2017535533A JP 2017520351 A JP2017520351 A JP 2017520351A JP 2017520351 A JP2017520351 A JP 2017520351A JP 2017535533 A JP2017535533 A JP 2017535533A
- Authority
- JP
- Japan
- Prior art keywords
- azilsartan
- solvate
- ethyl ester
- preparation
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005485 Azilsartan Substances 0.000 title claims abstract description 38
- 229960002731 azilsartan Drugs 0.000 title claims abstract description 38
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000012453 solvate Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 16
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 16
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 abstract description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 4
- 239000007787 solid Substances 0.000 abstract description 3
- 235000010290 biphenyl Nutrition 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000725 suspension Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 125000004494 ethyl ester group Chemical group 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- HSIAYPLCPXBCOP-UHFFFAOYSA-N 3-ethoxybenzimidazole-4-carboxylic acid Chemical compound C(C)ON1C=NC2=C1C(=CC=C2)C(=O)O HSIAYPLCPXBCOP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- LPKATDGGXXEZFL-UHFFFAOYSA-N 2,2,6,6-tetramethylheptan-4-one Chemical compound CC(C)(C)CC(=O)CC(C)(C)C LPKATDGGXXEZFL-UHFFFAOYSA-N 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- OWLFNOWZZXCCNU-UHFFFAOYSA-N CCOC(c1c2[n](Cc(cc3)ccc3-c(cccc3)c3C(N3)=NOC3=O)c(OCC)nc2ccc1)=O Chemical compound CCOC(c1c2[n](Cc(cc3)ccc3-c(cccc3)c3C(N3)=NOC3=O)c(OCC)nc2ccc1)=O OWLFNOWZZXCCNU-UHFFFAOYSA-N 0.000 description 1
- DVODSSZMOBIHGO-UHFFFAOYSA-N CCOC(c1c2[n](Cc(cc3)ccc3-c3ccccc3/C(/N)=N/O)c(OCC)nc2ccc1)=O Chemical compound CCOC(c1c2[n](Cc(cc3)ccc3-c3ccccc3/C(/N)=N/O)c(OCC)nc2ccc1)=O DVODSSZMOBIHGO-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000010431 corundum Substances 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZPV2014-702 | 2014-10-15 | ||
| CZ2014-702A CZ2014702A3 (cs) | 2014-10-15 | 2014-10-15 | Způsob přípravy vysoce čistého azilsartanu |
| PCT/CZ2015/000115 WO2016058563A1 (en) | 2014-10-15 | 2015-10-02 | A process for preparing highly pure azilsartan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2017535533A true JP2017535533A (ja) | 2017-11-30 |
Family
ID=54352451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520351A Pending JP2017535533A (ja) | 2014-10-15 | 2015-10-02 | 高純度のアジルサルタンを調製するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3207040A1 (cs) |
| JP (1) | JP2017535533A (cs) |
| CZ (1) | CZ2014702A3 (cs) |
| WO (1) | WO2016058563A1 (cs) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071519A (zh) * | 2016-01-28 | 2018-12-21 | 株式会社德山 | 阿齐沙坦及其制造方法 |
| CN115894472B (zh) * | 2022-12-14 | 2025-08-19 | 仁合益康集团有限公司 | 一种高纯度阿齐沙坦酯钾盐的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
| US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| WO2011063764A1 (zh) | 2009-11-30 | 2011-06-03 | 江苏豪森医药集团有限公司 | 阿齐沙坦有机胺盐及其制备方法和用途 |
| EP2666773B1 (en) | 2011-01-20 | 2017-07-26 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Organic amine salts of azilsartan, preparation method and use thereof |
| JP2014505097A (ja) | 2011-02-08 | 2014-02-27 | ジュビラント ライフ サイエンセズ リミテッド | アジルサルタンメドキソミルの改良製造方法 |
| CZ303505B6 (cs) * | 2011-04-11 | 2012-10-24 | Zentiva, K. S | Zpusob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátu a jejich prevedení na azilsartan |
| CZ304252B6 (cs) * | 2011-04-11 | 2014-01-29 | Zentiva, K. S. | Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan |
| KR101275092B1 (ko) | 2011-05-19 | 2013-06-17 | 한미정밀화학주식회사 | 아질사르탄의 개선된 제조방법 |
| WO2013088384A2 (en) | 2011-12-15 | 2013-06-20 | Jubilant Life Sciences Limited | Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof |
| CN103664920B (zh) * | 2012-09-24 | 2016-03-09 | 上海医药工业研究院 | 阿奇沙坦中间体及其与阿奇沙坦的制备方法 |
| WO2014049512A2 (en) | 2012-09-26 | 2014-04-03 | Lupin Limited | Novel process for preparation of azilsartan medoxomil |
| CZ305318B6 (cs) * | 2012-09-26 | 2015-07-29 | Zentiva, K.S. | Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu |
| US20140113942A1 (en) | 2012-10-12 | 2014-04-24 | Cadila Healthcare Limited | Process for the preparation and purification of azilsartan medoxomil |
| CN103664921B (zh) * | 2013-11-27 | 2016-08-24 | 湖南千金湘江药业股份有限公司 | 一种阿齐沙坦晶型a及其制备方法 |
-
2014
- 2014-10-15 CZ CZ2014-702A patent/CZ2014702A3/cs unknown
-
2015
- 2015-10-02 EP EP15784925.8A patent/EP3207040A1/en not_active Withdrawn
- 2015-10-02 WO PCT/CZ2015/000115 patent/WO2016058563A1/en active Application Filing
- 2015-10-02 JP JP2017520351A patent/JP2017535533A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3207040A1 (en) | 2017-08-23 |
| CZ2014702A3 (cs) | 2016-04-27 |
| WO2016058563A1 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6799037B2 (ja) | 化学的方法 | |
| AU7081900A (en) | Bicyclic androgen and progesterone receptor modulator compounds and methods | |
| JP2009504792A (ja) | 化合物 | |
| US10040793B2 (en) | Key intermediates and impurities of the synthesis of Apixaban: Apixaban glycol esters | |
| WO2013042067A1 (en) | Process for the preparation of potassium salt of azilsartan medoxomil | |
| EP2900662A1 (en) | A method of preparing a highly pure potassium salt of azilsartan medoxomil | |
| WO2016002918A1 (ja) | インドール化合物の製造方法 | |
| US10654803B2 (en) | Transition metal-catalyzed protodecarboxylation of alpha-halo-acrylic acid derivatives | |
| JP2017535533A (ja) | 高純度のアジルサルタンを調製するための方法 | |
| EP2872499A1 (en) | Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates | |
| JP2020518573A (ja) | ２−（［１，２，３］トリアゾール−２−イル）−安息香酸誘導体の製造 | |
| JP2010254692A (ja) | パリペリドンの精製方法 | |
| CZ2012274A3 (cs) | Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu | |
| WO2013042066A1 (en) | Process for the preparation of azilsartan medoxomil | |
| JP2012516327A (ja) | カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法 | |
| JPWO2012073991A1 (ja) | ピロール誘導体及びその製造方法 | |
| HK1070357A1 (zh) | 5-取代異苯並呋喃的製備方法 | |
| HK1070357B (en) | Process for the preparation of 5-substituted isobenzofurans | |
| JP2018140944A (ja) | ピラゾール化合物の製造方法およびその中間体 | |
| CZ2015579A3 (cs) | Krystalická forma A Rilpivirin Adipátu a způsob její přípravy |